Please login to the form below

Not currently logged in
Email:
Password:

Opdivo

This page shows the latest Opdivo news and features for those working in and with pharma, biotech and healthcare.

BMS scores first oesophageal cancer nod for Opdivo in Japan

BMS scores first oesophageal cancer nod for Opdivo in Japan

Opdivo met the primary endpoint of overall survival (OS), demonstrating a 23% reduction in the risk of death and a 2.5 month improvement in OS when compared to chemotherapy. ... The survival benefit with Opdivo treatment was observed regardless of tumour

Latest news

More from news
Approximately 145 fully matching, plus 214 partially matching documents found.

Latest Intelligence

  • 20 for 2020 – Five pharma companies to watch 20 for 2020 – Five pharma companies to watch

    The merger was completed shortly after BMS reported the first decline in quarterly sales of its immuno-oncology blockbuster Opdivo (nivolumab) since its launch five years ago, and 2020 is viewed ... Opdivo is being squeezed out of the market by Merck &Co/

  • Encouraging signs in biomarker R&D Encouraging signs in biomarker R&D

    In June 2018, Bristol Myers-Squibb sought approval for Opdivo and low-dose Yervoy in lung cancer in patients with a TMB of greater than ten mutations per megabase. ... impact of Opdivo plus Yervoy on OS in first-line NSCLC patients’.

  • 2019: CRISPR and therapeutic gene editing comes of age 2019: CRISPR and therapeutic gene editing comes of age

    The cells were gene-edited to lack PD-1, the immune checkpoint targeted by drugs such as Merck &Co’s Keytruda (pembrolizumab) and Bristol-Myers Squibb’s Opdivo (nivolumab), and the

  • Immuno-oncology in 2019: the rapid evolution continues Immuno-oncology in 2019: the rapid evolution continues

    Opdivo will be just behind on around $6.8bn, with more rapid growth for both therapies expected this year. ... Opdivo is not a contender as a monotherapy or combination with chemo in front-line NSCLC, having failed key trials in the last few years.

  • Is China ready for a pharmaceutical gold rush?

    Indeed, BMS will pitch Opdivo at half the US list price, determining the true value of market access. ... Competition time. At the same time, Merck’s PD-1 agent, Keytruda, is hot on Opdivo’s heels.

More from intelligence
Approximately 0 fully matching, plus 14 partially matching documents found.

Latest appointments

  • BMS appoints new commercial leader, Davies joins Eisai and more BMS appoints new commercial leader, Davies joins Eisai and more

    The move comes at a challenging time for BMS, as its blockbuster immunotherapy Opdivo has just been overtaken in global revenues by its arch-rival, Merck &Co's Keytruda. ... BMS looks unlikely to take the lead again, but Boerner can ensure Opdivo remains

  • BMS appoints oncology development head BMS appoints oncology development head

    On moving to the US in 2006, Dr Namouni took over responsibility for metastatic colorectal cancer treatment Erbitux (cetuximab), before serving as development lead for Opdivo (nivolumab) and Yervoy (ipilimumab).

More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.

Latest from PMHub

More from PMHub
Approximately 1 fully matching, plus 6 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Dice Medical Communications

Dice Medical Communications is an independent communications agency that works with our clients to help launch, build, and continually develop...

Latest intelligence

BRIC markets
BRIC markets
Why these countries offer an opportunity for pharma despite a slowdown...
Obstetrics Virtual Journal Club: An Impetus Digital Customer Success Story
Our online solutions are not just for advisory boards - find out how one client leveraged the Impetus InSite Platform® for a virtual journal club....
Ludovic Helfgott
Novo Nordisk awakens its ‘Sleeping Beauty’
Biopharm emerges from troubled times to hit ‘solid growth’, says executive vice president Ludovic Helfgott...

Infographics